We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Conference

Global Congress on Prostate Cancer 2020

October 10-14, 2020 · Online

26 submissions

Treatment sequencing in metastatic castration resistant prostate cancer (mCRPC) after progression under an androgen receptor signaling inhibitor (ARSI) and to docetaxel: results in long responders to previous ARSIs

Castration-resistant prostate cancer - Cabazitaxel as a rescue

Treatments sequencing in metastatic prostate cancer new diagnosed: more opportunities in progression free survival. A case report

abiraterone acetate

steroid switch

Validating SGK1 as a Therapeutic Target in Prostate Cancer

Validating

SGK1

Therapeutic

Target

prostate

Overall Survival, Disease Progression, and Quality of Life of Metastatic CRPC patient on Enzalutamide Treatment

CRPC

Enzalutamide

Quality of life

Chemoprevention of carcinogen-induced prostate cancer by polyprenols from coniferous trees: experimental study

prostate cancer

chemoprevention

Symptomatic peritoneal carcinomatosis as the initial presentation of metastatic prostate cancer

Prostate Cancer

Peritoneal Metastasis

About a case highlighting the place of metastasis-directed therapy in isolated liver metastases in prostate cancer

prostate cancer

oligometastatic

Prostate cancer in Maroni area, French Guiana: the lack of access to health facilities penalizes patients

Abstract title: Mapping the quality of prostate cancer care in Europe

care delivery

healthcare provider

Factors predicting outcome with multi-rsistant advanced prostate cancer treated with prostate specific membrane antigen radioligand therapy. A systematic review and meta-analysis

Prostate cancer

Outcomes of high-risk prostate cancer after robotic-assisted radical prostatectomy: Real-life experience

high-risk prostate cancer

Abiraterone acetate withdrawal syndrome in metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone

Abiraterone acetate

Treatment of castration-resistant prostate cancer

Prostate Cancer

Castration-resistant

Impact of modern imaging tools on management of prostate cancer, a single center evaluation.

prostate cancer

PSMA-PET

imaging technique

Detection rate of clinically significant cancer using magnetic resonance imaging/ultrasound cognitive-fusion prostate biopsy

clinically significant prostate cancer

Prostate ultrahypofractionation in the COVID-19 era: potential impact on a UK centre

Prostate Cancer

COVID-19

Isolated peritoneal carcinomatosis in prostate cancer, maybe not so rare. About a case highlighting the importance of modern imaging and efficacy of abiraterone acetate.

prostate cancer

peritoneal carcinomatosis

Neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR) and its kinetics as prognostic markers for patients with metastatic castration resistant prostate cancer treated with Enzalutamide

biomarkers

neutrophil-to-lymphocyte ratio

THE PATHOLOGICAL FEATURES OF PROSTATE CANCER IN SOUTH AFRICAN MEN: WHAT IS THE PREVALENCE OF LOCAL INVASION AT DIAGNOSIS?

prostate cancer

perineural invasion

Final overall survival (OS) analysis of PROfound: olaparib vs physician's choice of enzalutamide or abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

Winner

PATIO - empowering prostate cancer patients in science

prostate cancer

open innovation

Optimization of PET protocol and interrater reliability of 18F-PSMA-11 imaging of prostate cancer

prostate cancer

PSMA

18F-PSMA-11

Rate of adverse morphological features after radical prostatectomy

Submission not yet received

1 2

Company

Legal

Home About Contact

Imprint Terms of Service Privacy Policy